Sensus Healthcare, Inc. ( SRTS ) NASDAQ Capital Market

Cena: 4.72 ( -0.44% )

Aktualizacja 06-20 21:54
NASDAQ Capital Market
Branża: Medical - Devices
Statystyki
Dywidendy
Rekomendacje
Wyceny
Wskaźniki
Analiza techniczna

Notowania:

Informacje o spółce:
Sektor: Zdrowie
Branża: Medical - Devices
Zatrudnienie: 35
Giełda: NASDAQ Capital Market
Ilość akcji w obrocie: 79%
Ilość akcji: 16 374 199
Debiut giełdowy: 2016-07-26
WWW: https://www.sensushealthcare.com
CEO: Mr. Joseph C. Sardano
Adres: 851 Broken Sound Parkway NW
Siedziba: 33487 Boca Raton
ISIN: US81728J1097
Opis firmy:

Sensus Healthcare, Inc., firma zajmująca się urządzeniami medycznymi, produkuje i sprzedaje urządzenia radioterapii dla świadczeniodawców na całym świecie. Firma korzysta z powierzchniowej radioterapii (SRT), technologii rentgenowskiej o niskiej energii w swoim portfolio urządzeń do leczenia. Oferuje SRT-100, powierzchowny system radioterapii fotonowej, który zapewnia pacjentom alternatywę dla operacji leczenia nowotworów skóry niemelanoma, w tym raku komórek podstawowych i płaskonabłonkowych, a także innych stanów skóry, takich jak keloidy; oraz SRT-100 Vision, który zapewnia użytkownikowi aplikację planowania leczenia SRT, która integruje wbudowany moduł obrazowania ultrasonograficznego o wysokiej częstotliwości, analizę guza objętościowego, planowanie marginesów wiązki i parametry dozymetrii. Firma zapewnia również SRT-100 Plus; Program serwisowy Sentinel, który oferuje klientom ochronę swoich systemów; oraz usługi wynajmu laserowego w biurze. Ponadto sprzedaje jednorazowe zamienniki ochrony ołowiu; oraz elementy bezpieczeństwa promieniowania jednorazowego, takie jak fartuchy i tarcze oczu, ultradźwiękowy film sondy oraz jednorazowe końcówki aplikatorów do leczenia zmian o różnych rozmiarach i różnych obszarach ciała. Sensus Healthcare, Inc. został włączony w 2010 roku i ma siedzibę w Boca Raton na Florydzie.

Wskaźniki finansowe
Kapitalizacja (USD) 77 607 244
Aktywa: 59 858 000
Cena: 4.72
Wskaźnik Altman Z-Score: 17.8
Stabilny (niskie ryzyko bankructwa)
Dywidenda: 0
P/E: 42.9
Ilość akcji w obrocie: 79%
Średni wolumen: 96 045
Ilość akcji 16 445 000
Wskaźniki finansowe
Przychody TTM 41 307 000
Zobowiązania: 5 727 000
Przedział 52 tyg.: 4.01 - 9.329
Piotroski F-Score: 6
Umiarkowany (średnia jakość finansowa)
EPS: 0.1
P/E branży: 26.8
Beta: 1.045
Raport okresowy: 2025-08-06
WWW: https://www.sensushealthcare.com
Zarząd
Imie i Nazwisko Stanowisko Wynagrodzenie Rok urodzenia
Mr. Joseph C. Sardano Co-Founder, Chairman & Chief Executive Officer 687 599 1953
Mr. Michael J. Sardano President, General Counsel, Corporate Secretary & Director 362 933 1988
Mr. Javier Rampolla Chief Financial Officer 357 062 1973
Ms. Magdalena Martinez Chief Operating Officer 0 1990
Mr. Emiliano Sosa Chief Technology Officer 0 1978
Ms. Stephanie Tipton Vice President of Marketing 0 0
Wiadomości dla Sensus Healthcare, Inc.
Tytuł Treść Źródło Aktualizacja Link
Sensus Healthcare, Inc. (SRTS) Q1 2025 Earnings Call Transcript Sensus Healthcare, Inc. (NASDAQ:SRTS ) Q1 2025 Earnings Conference Call May 15, 2025 4:30 PM ET Company Participants Tirth Patel - Alliance Advisors, IR Joe Sardano - Chairman and CEO Michael Sardano - President & General Counsel Javier Rampolla - Chief Financial Officer Conference Call Participants Yi Chen - H. C. Wainwright Jason Wittis - Roth Capital Jeremy Pearlman - Maxim Group Ben Haynor - Lake Street Capital Markets Operator Good day, and welcome to the Sensus Healthcare First Quarter 2025 Financial Results Conference Call. seekingalpha.com 2025-05-15 23:58:47 Czytaj oryginał (ang.)
Sensus Healthcare, Inc. (SRTS) Reports Q1 Loss, Tops Revenue Estimates Sensus Healthcare, Inc. (SRTS) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of $0.04. This compares to earnings of $0.14 per share a year ago. zacks.com 2025-05-15 22:26:06 Czytaj oryginał (ang.)
Sensus Healthcare Reports First Quarter 2025 Financial Results BOCA RATON, Fla.--(BUSINESS WIRE)---- $SRTS--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces financial results for the three months ended March 31, 2025. Highlights of the first quarter of 2025 include the following: Revenues were $8.3 million Net loss was $2.6 million, or $(0.16) per share Shipped 21 superficial radiotherapy (SRT. businesswire.com 2025-05-15 20:05:00 Czytaj oryginał (ang.)
Sensus Healthcare, Inc. (SRTS) Stock Falls Amid Market Uptick: What Investors Need to Know In the latest trading session, Sensus Healthcare, Inc. (SRTS) closed at $4.22, marking a -0.47% move from the previous day. zacks.com 2025-05-07 23:20:55 Czytaj oryginał (ang.)
Sensus Healthcare Celebrates Skin Cancer Awareness Month by Promoting Awareness and Spotlighting its Patient-Friendly, Non-Invasive Treatments BOCA RATON, Fla.--(BUSINESS WIRE)--May is Skin Cancer Awareness Month and Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, is leveraging a wide range of activities to draw attention to the importance of prevention, early detection and treatment of the most common form of cancer that affects millions of people worldwide. Throughout. businesswire.com 2025-05-01 20:30:00 Czytaj oryginał (ang.)
Earnings Preview: Sensus Healthcare, Inc. (SRTS) Q1 Earnings Expected to Decline Sensus Healthcare (SRTS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. zacks.com 2025-05-01 15:06:28 Czytaj oryginał (ang.)
Is Sensus Healthcare (SRTS) a Buy as Wall Street Analysts Look Optimistic? Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter? zacks.com 2025-04-25 14:36:17 Czytaj oryginał (ang.)
Sensus Healthcare, Inc. (SRTS) Rises Yet Lags Behind Market: Some Facts Worth Knowing In the latest trading session, Sensus Healthcare, Inc. (SRTS) closed at $4.69, marking a +1.3% move from the previous day. zacks.com 2025-04-23 23:21:18 Czytaj oryginał (ang.)
Sensus Healthcare, Inc. (SRTS) Increases Despite Market Slip: Here's What You Need to Know Sensus Healthcare, Inc. (SRTS) reachead $4.48 at the closing of the latest trading day, reflecting a +0.45% change compared to its last close. zacks.com 2025-04-07 23:20:41 Czytaj oryginał (ang.)
Sensus Healthcare, Inc. (SRTS) Rises As Market Takes a Dip: Key Facts Sensus Healthcare, Inc. (SRTS) closed the most recent trading day at $4.69, moving +1.08% from the previous trading session. zacks.com 2025-03-27 21:20:41 Czytaj oryginał (ang.)
Here's Why Sensus Healthcare, Inc. (SRTS) Gained But Lagged the Market Today Sensus Healthcare, Inc. (SRTS) closed the most recent trading day at $4.78, moving +0.84% from the previous trading session. zacks.com 2025-03-19 21:20:35 Czytaj oryginał (ang.)
Brokers Suggest Investing in Sensus Healthcare (SRTS): Read This Before Placing a Bet When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important? zacks.com 2025-03-07 12:30:46 Czytaj oryginał (ang.)
Sensus Healthcare to Showcase Commercial and Late-Stage Products at the American Academy of Dermatology Annual Meeting BOCA RATON, Fla.--(BUSINESS WIRE)---- $SRTS--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces it will be showcasing its full line of commercial Superficial Radiotherapy (SRT) products including the SRT-100®, SRT-100+ and SRT-100 Vision™ systems, along with several innovative pre-commercial products, at the 2025 American Academy of. businesswire.com 2025-03-06 10:00:00 Czytaj oryginał (ang.)
Sensus Healthcare: A Tough Q1 2025 Awaits Ahead Q4 2024 showed a significant miss in profitability despite a 4% YoY sales growth; gross profit margin dropped due to a one-time discount for a new big client. The FDA initiatives are interesting, but they will bring a slowdown in sales as they are fully rolled out. Management has warned of a Q1 2025 with considerably lower sales due to the Fair Deal Agreements and seasonal factors. seekingalpha.com 2025-02-07 11:04:47 Czytaj oryginał (ang.)
Sensus Healthcare, Inc. (SRTS) Q4 2024 Earnings Call Transcript Sensus Healthcare, Inc. (NASDAQ:SRTS ) Q4 2024 Earnings Conference Call February 5, 2025 4:30 PM ET Company Participants Tirth Patel - Alliance Advisors, IR Joe Sardano - Chairman and CEO Michael Sardano - President & General Counsel Javier Rampolla - CFO Conference Call Participants Jeremy Pearlman - Maxim Group Arsalan Cameron - Roth Capital Partners Ben Haynor - Lake Street Capital Markets Operator Good day, and welcome to the Sensus Healthcare Fourth Quarter 2024 Financial Results Conference Call. [Operator Instructions]. seekingalpha.com 2025-02-06 00:22:03 Czytaj oryginał (ang.)
Sensus Healthcare, Inc. (SRTS) Lags Q4 Earnings Estimates Sensus Healthcare, Inc. (SRTS) came out with quarterly earnings of $0.09 per share, missing the Zacks Consensus Estimate of $0.10 per share. This compares to earnings of $0.26 per share a year ago. zacks.com 2025-02-05 21:06:24 Czytaj oryginał (ang.)
Sensus Healthcare Reports Fourth Quarter and Full Year 2024 Financial Results BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces financial results for the three and 12 months ended December 31, 2024. Highlights include the following: Revenues were $13.1 million for the fourth quarter and $41.8 million for the year, up 4% and 71% respectively, compared with the prior. businesswire.com 2025-02-05 18:05:00 Czytaj oryginał (ang.)
Sensus Healthcare (SRTS) Moves 19.9% Higher: Will This Strength Last? Sensus Healthcare (SRTS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term. zacks.com 2025-02-03 09:26:26 Czytaj oryginał (ang.)
Sensus Healthcare, Inc. (SRTS) Exceeds Market Returns: Some Facts to Consider Sensus Healthcare, Inc. (SRTS) closed at $6.92 in the latest trading session, marking a +1.91% move from the prior day. zacks.com 2025-01-28 21:21:26 Czytaj oryginał (ang.)
Sensus Healthcare, Inc. (SRTS) Outperforms Broader Market: What You Need to Know Sensus Healthcare, Inc. (SRTS) reachead $6.77 at the closing of the latest trading day, reflecting a +1.96% change compared to its last close. zacks.com 2025-01-15 21:21:27 Czytaj oryginał (ang.)
Sensus Healthcare, Inc. (SRTS) Stock Slides as Market Rises: Facts to Know Before You Trade The latest trading day saw Sensus Healthcare, Inc. (SRTS) settling at $6.83, representing a -1.87% change from its previous close. zacks.com 2025-01-08 21:20:38 Czytaj oryginał (ang.)
Sensus Healthcare, Inc. (SRTS) Sees a More Significant Dip Than Broader Market: Some Facts to Know The latest trading day saw Sensus Healthcare, Inc. (SRTS) settling at $7.21, representing a -1.77% change from its previous close. zacks.com 2024-12-27 21:20:29 Czytaj oryginał (ang.)
Sensus Healthcare (SRTS) Surges 7.9%: Is This an Indication of Further Gains? Sensus Healthcare (SRTS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term. zacks.com 2024-12-27 08:17:15 Czytaj oryginał (ang.)
Sensus Healthcare, Inc. (SRTS) Stock Slides as Market Rises: Facts to Know Before You Trade In the latest trading session, Sensus Healthcare, Inc. (SRTS) closed at $7.10, marking a -1.53% move from the previous day. zacks.com 2024-12-20 21:16:13 Czytaj oryginał (ang.)
Wall Street Bulls Look Optimistic About Sensus Healthcare (SRTS): Should You Buy? When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important? zacks.com 2024-12-05 12:31:14 Czytaj oryginał (ang.)
Wall Street Analysts Believe Sensus Healthcare (SRTS) Could Rally 36.01%: Here's is How to Trade The average of price targets set by Wall Street analysts indicates a potential upside of 36% in Sensus Healthcare (SRTS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. zacks.com 2024-12-04 12:56:15 Czytaj oryginał (ang.)
Is Sensus Healthcare (SRTS) Outperforming Other Medical Stocks This Year? Here is how Sensus Healthcare, Inc. (SRTS) and Alnylam Pharmaceuticals (ALNY) have performed compared to their sector so far this year. zacks.com 2024-12-04 12:40:49 Czytaj oryginał (ang.)
Pompano Veterinary Oncology Partners with Sensus Healthcare to Provide First Superficial Radiotherapy Services in a Mobile Configuration Full-service medical oncology practice to pioneer the use of SRT to treat companion animals for both home and veterinary clinic visits globenewswire.com 2024-12-04 10:30:00 Czytaj oryginał (ang.)
Wall Street Analysts See a 39.66% Upside in Sensus Healthcare (SRTS): Can the Stock Really Move This High? The mean of analysts' price targets for Sensus Healthcare (SRTS) points to a 39.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. zacks.com 2024-11-18 13:00:43 Czytaj oryginał (ang.)
What Makes Sensus Healthcare (SRTS) a Good Fit for 'Trend Investing' Sensus Healthcare (SRTS) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen. zacks.com 2024-11-18 11:50:17 Czytaj oryginał (ang.)
REVISED - Sensus Healthcare Reports Third Quarter 2024 Financial Results With Revenues More than Doubling Versus 2023 Third Quarter This revised news release replaces the one issued on November 14, 2024, contains several non-financial changes throughout and removes the name of and references to a new customer, at the customer's request. The agreement with the new customer remains in effect. globenewswire.com 2024-11-17 22:32:00 Czytaj oryginał (ang.)
Sensus Healthcare: Q3 Results Showed That The Stock Is Undervalued Sensus Healthcare's Q3 results exceeded expectations with 127% YoY revenue growth and EPS of $0.07, showcasing strong demand recovery and effective management strategies. The Fair Deal Agreement and new FDA contracts, including a major deal with Platinum Dermatology, promise recurring revenue and reduced client concentration risk. Despite impressive financial performance, the stock saw minimal movement, presenting a potential 150% upside over the next five years under my assumptions. seekingalpha.com 2024-11-15 15:46:36 Czytaj oryginał (ang.)
Sensus Healthcare, Inc. (SRTS) Q3 2024 Earnings Call Transcript Sensus Healthcare, Inc. (SRTS) Q3 2024 Earnings Call Transcript seekingalpha.com 2024-11-14 20:40:29 Czytaj oryginał (ang.)
Sensus Healthcare, Inc. (SRTS) Surpasses Q3 Earnings and Revenue Estimates Sensus Healthcare, Inc. (SRTS) came out with quarterly earnings of $0.07 per share, beating the Zacks Consensus Estimate of a loss of $0.02 per share. This compares to loss of $0.09 per share a year ago. zacks.com 2024-11-14 18:26:18 Czytaj oryginał (ang.)
Sensus Healthcare Reports Third Quarter 2024 Financial Results With Revenues More than Doubling Versus 2023 Third Quarter Revenues of $8.8 million compare with $3.9 million in the prior-year quarter, adjusted EBITDA (a non-GAAP measure) of $1.6 million compares with negative $1.7 million a year ago Signed a Fair Deal Agreement with Platinum Dermatology, a leading dermatology network with 130 clinics across the U.S. Conference call begins at 4:30 p.m. Eastern time today BOCA RATON, Fla. globenewswire.com 2024-11-14 14:06:00 Czytaj oryginał (ang.)
Sensus Healthcare, Inc. (SRTS) Outperforms Broader Market: What You Need to Know Sensus Healthcare, Inc. (SRTS) reachead $6.44 at the closing of the latest trading day, reflecting a +1.58% change compared to its last close. zacks.com 2024-10-24 23:20:17 Czytaj oryginał (ang.)
Sensus Healthcare (SRTS) is on the Move, Here's Why the Trend Could be Sustainable Sensus Healthcare (SRTS) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen. zacks.com 2024-10-07 13:51:15 Czytaj oryginał (ang.)
Sensus Healthcare, Inc. (SRTS) Ascends While Market Falls: Some Facts to Note The latest trading day saw Sensus Healthcare, Inc. (SRTS) settling at $5.90, representing a +1.72% change from its previous close. zacks.com 2024-10-01 23:21:28 Czytaj oryginał (ang.)
All You Need to Know About Sensus Healthcare (SRTS) Rating Upgrade to Strong Buy Sensus Healthcare (SRTS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. zacks.com 2024-10-01 17:00:26 Czytaj oryginał (ang.)
Sensus Healthcare, Inc. (SRTS) Falls More Steeply Than Broader Market: What Investors Need to Know Sensus Healthcare, Inc. (SRTS) closed at $5.80 in the latest trading session, marking a -1.86% move from the prior day. zacks.com 2024-09-20 23:21:09 Czytaj oryginał (ang.)
Sensus Healthcare, Inc. (SRTS) is a Great Momentum Stock: Should You Buy? Does Sensus Healthcare, Inc. (SRTS) have what it takes to be a top stock pick for momentum investors? Let's find out. zacks.com 2024-08-30 17:01:19 Czytaj oryginał (ang.)